IPP Bureau
RPG Life Sciences appoints Deepak Shukla as Chief Executive - API Business
By IPP Bureau - July 27, 2025
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
By IPP Bureau - July 27, 2025
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Concord Biotech successfully completes Russian GMP inspection at its API facility
By IPP Bureau - July 27, 2025
The inspection was conducted from July 22-25, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
By IPP Bureau - July 27, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
By IPP Bureau - July 27, 2025
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr
By IPP Bureau - July 26, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr
By IPP Bureau - July 26, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
.jpg "Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr")
Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr
By IPP Bureau - July 26, 2025
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr
By IPP Bureau - July 26, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Indoco receives EU GMP certificate for its sterile manufacturing facility in Goa
By IPP Bureau - July 26, 2025
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs
By IPP Bureau - July 24, 2025
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
NATCO Pharma API unit in Mekaguda receives EIR from USFDA
By IPP Bureau - July 24, 2025
The company received one observation in the Form-483
Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products
By IPP Bureau - July 24, 2025
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Zydus receives tentative approval from USFDA for Ibrutinib tablets
By IPP Bureau - July 24, 2025
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
By IPP Bureau - July 24, 2025
Revenue increased 11.4 per cent to Rs. 8,545 crore
